Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-10-28
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 615740 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for anti-inflammatories ('LIS 2001a Anti-inflammatories'). The contest included the active ingredients that were in accordance with the tender documentation, Annex 3 — the active ingredients list. After the contest, tenders were received for Nebcina inj 40 mg/ml, product No 66501, ATC code J01GB01, where the supplier has a marketing licence.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for anti-inflammatories ('LIS 2001a Anti-inflammatories').
The contest included the active ingredients that were in accordance with the tender documentation, Annex 3 — the active ingredients list. After the contest, tenders were received for Nebcina inj 40 mg/ml, product No 66501, ATC code J01GB01, where the supplier has a marketing licence. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. No other suppliers have a marketing licence for the medicine classified in ATC-code J01GB01 for injection. Based on this information, LIS intends to enter into a contract between the regional health authorities (the contracting authorities) Eurocept B.V. (the Supplier) as an additional contract for LIS 2001a, i.e. the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for these active ingredients.
The health companies that are under the regional health trusts have an option to join the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Eurocept B.V. can deliver the product in the contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. Cf. the Public Procurement Regulations §13-4, letter b, No 3. LIS requests that those who have objections to this submit feedback before the waiting period expires on 15.11.2019. If no objections are received, a contract will be signed after the waiting period has expired.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for anti-inflammatories ('LIS 2001a Anti-inflammatories').
The contest included the active ingredients that were in accordance with the tender documentation, Annex 3 — the active ingredients list. After the contest, tenders were received for Nebcina inj 40 mg/ml, product No 66501, ATC code J01GB01, where the supplier has a marketing licence. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. No other suppliers have a marketing licence for the medicine classified in ATC-code J01GB01 for injection. Based on this information, LIS intends to enter into a contract between the Regioanl Health Authorities (the Contracting Authorities) Eurocept B.V. (the Supplier) as an additional contract for LIS 2001a, i.e. the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for these active ingredients.
The health companies that are under the regional health trusts have an option to join the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Eurocept B.V. can deliver the product in the contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. Cf. the Public Procurement Regulations §13-4, letter b, No 3. LIS requests that those who have objections to this submit feedback before the waiting period expires on 15.11.2019. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Eurocept B.V.
Award value: 615740